A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
A Phase 1 Study of MGD020 as a Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Sponsor: Department of Health and Human Services
A PHASE1 clinical study on Human Immunodeficiency Virus I Infection and Human Immunodeficiency Virus Type 1, this trial is completed. The trial is conducted by Department of Health and Human Services and has accumulated 11 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health and Human Services
- MacroGenics
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .